Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Ranging Study of IMB-1018972 in Type 2 Diabetes Patients With Cardiac Energetic Assessment
2020-003280-26Phase 2Unknown
- Sponsor
- Imbria Pharmaceuticals
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ninerafaxstat in type 2 diabetes mellitus (T2DM) and diabetic cardiomyopathy (DCM), sponsored by Imbria Pharmaceuticals. Primary endpoints: Change in myocardial PCr/ATP ratio at rest and Change in myocardial PCr/ATP ratio during dobutamine stress. Status: unknown.
02
Drugs
ninerafaxstat
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2020-003280-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003280-26.